Clinical trials
CAR clinical trials
Below are recruiting car clinical trials, each written for real people, not researchers. We’re tracking 733 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06847269RecruitingPhase 2
CAR T cell therapy for children and young adults with CD19+ leukemia
This trial tests an immunotherapy called CAR T cells for leukemia that has come back or is hard to treat. It aims to use your own immune cells to fight the cancer.
Memphis, TennesseeAges Up to 21 years - NCT06838832RecruitingPhase 1/Phase 2
New CAR-T cell therapy for relapsed B-cell lymphoma
This trial tests a new treatment made from your own immune cells (gamma-delta T cells) that are engineered to find and kill CD19-positive lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma whose cancer has not responded to or has returned after at least two standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT06830031RecruitingPhase 1
C402-CD19-CAR treatment for relapsed or refractory B-cell lymphoma
This trial tests a new CAR-T cell therapy called C402-CD19-CAR for people with certain types of B-cell lymphoma that have come back or not responded to previous treatments. The treatment uses your own immune cells to target and kill cancer cells that have a protein called CD19 on their surface.
TianjinAges 18–75 - NCT06828042RecruitingPhase 1/Phase 2
CAR-γδT cells for refractory autoimmune diseases
This trial tests a new type of immune cell therapy (CAR-γδT cells) that targets a protein called CD19 on your own B cells. It is for people with certain autoimmune diseases that have not gotten better with standard treatments. The goal is to see if this therapy can safely control the disease.
BeijingAges 18–80 - NCT06827782Enrolling by invitationPhase 1
Cord blood CAR-NK cells for relapsed CNS lymphoma
This trial tests a new treatment using specially engineered immune cells from cord blood to target and kill cancer cells in the brain or spine. It is for people whose central nervous system lymphoma has not responded to or has returned after previous treatments.
Hangzhou, ZhejiangAges 18–75 - NCT06821048RecruitingPhase 1
CAR-T cells targeting CEA for advanced solid tumors
This trial tests a new treatment called CAR-T cells that are designed to attack cancer cells positive for CEA protein. It's for people with advanced solid tumors like colorectal or lung cancer who have run out of standard options.
Hangzhou, ZhejiangAges 18 years+ - NCT06815432RecruitingPhase 1
GPC-3 CAR T cells for recurrent GPC-3 positive glioblastoma
This trial tests whether a special type of immune cell (called CAR T cells) can fight a brain tumor called glioblastoma that has come back. The cells are made to target a protein on the tumor cells, and the study will see if this treatment is safe and helpful.
Houston, TexasAges 21–70 - NCT06793475Recruiting
Aponermin before CAR-T for multiple myeloma with extramedullary disease
This trial tests whether a drug called aponermin, given before CAR-T cell therapy, can help people with multiple myeloma that has come back or not responded to treatment and has spread to soft tissues (extramedullary disease). The goal is to make the CAR-T therapy work better.
BeijingAges 18 years+ - NCT06793449RecruitingPhase 2
BCMA CAR-T vs. stem cell transplant for multiple myeloma
This trial tests whether a newer immune treatment (BCMA CAR-T) works better than a stem cell transplant for people with multiple myeloma who are able to have a transplant. Both treatments aim to kill myeloma cells, but CAR-T uses your own engineered immune cells.
TianjinAges 18–70 - NCT06786533RecruitingPhase 1
CAR-T cells for hard-to-treat AML
This study tests a new treatment made from your own immune cells, engineered to find and attack AML cells. It is for patients whose leukemia has not responded to standard therapy or has come back after treatment, including after a stem cell transplant.
Houston, TexasAges 12 years+ - NCT06792799RecruitingEarly Phase 1
CAR-NK cells for B-cell autoimmune diseases
This early phase trial tests a new treatment made from immune cells (CAR-NK cells) that target and destroy overactive B cells. It may help people with lupus, certain kidney diseases, or nephrotic syndrome that hasn't responded to standard therapies.
Hangzhou, ZhejiangAges 3 years+ - NCT06622694RecruitingPhase 1
CD7 car-t cells for severe aplastic anemia
This trial tests a new treatment called CD7 car-t cells (rd13-02) for people with severe aplastic anemia that has not responded to standard therapy or has come back. The goal is to see if this therapy can help restore normal blood cell production.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06777979RecruitingPhase 1
CAR T cell therapy for children with hard-to-treat leukemia
This trial tests a special kind of immune cell therapy that targets two markers (CD19 and CD22) on leukemia cells. It is for children and teens whose leukemia has come back multiple times or has not responded to standard treatment.
Memphis, TennesseeAges Up to 21 years - NCT06735690RecruitingEarly Phase 1
Immune cells plus vaccine after stem cell transplant for leukemia
This trial is for people with high-risk acute lymphoblastic leukemia who are getting a stem cell transplant from a family donor. After transplant, you'd receive a treatment that combines specially designed immune cells (CAR T cells) that target your leukemia, plus a vaccine that helps those cells work better.
Duarte, CaliforniaAges 18 years+ - NCT05979363RecruitingPhase 2
CAR-T cell therapy for plasma cell leukemia patients
This trial tests a combination of drugs (bortezomib, lenalidomide, and dexamethasone) followed by a special cell therapy called CAR-T that targets a protein (BCMA) on cancer cells. It is for people with a rare and aggressive blood cancer called primary plasma cell leukemia who are not able to have a stem cell transplant.
TianjinAges 18–75 - NCT06707259RecruitingPhase 1
Cord blood CAR NK cells for B-cell lymphoma
This trial tests a new treatment using immune cells from cord blood, called CAR NK cells, to fight certain types of B-cell lymphoma that have come back or not responded to other treatments. It is designed for people who have tried at least two prior therapies.
Hangzhou, ZhejiangAges 18–75 - NCT06711146RecruitingEarly Phase 1
CAR T-cell therapy for active lupus
This study tests a new treatment using a type of immune cell therapy (CAR T-cells) for people with moderate to severe systemic lupus erythematosus (SLE) that has not responded well to standard treatments. The therapy aims to reset the immune system to reduce lupus activity.
Hangzhou, ZhejiangAges 18 years+ - NCT06696846RecruitingPhase 1
CAR-NK cell therapy for T cell lymphoma and acute myeloid leukemia
This trial tests an immune cell treatment (CAR-NK cells) targeting a protein called CD70 found on cancer cells. It's for people with T cell lymphoma or acute myeloid leukemia that has come back or not responded to other treatments.
Hangzhou, ZhejiangAges 18–75 - NCT06690827RecruitingPhase 1
Cd123-targeted car-nk cells for relapsed aml or bpdcn
This trial tests a new treatment using your own immune cells (natural killer cells) that are modified to find and attack cancer cells with a marker called CD123. It is for people with acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN) that has come back or not responded to standard therapies.
Wuhan, HubeiAges 18–75 - NCT05827835RecruitingPhase 1/Phase 2
CD7 CAR-T treatment then stem cell transplant for CD7 leukemia
This trial tests a new immune cell therapy (CD7 CAR-T) given as a bridge to a stem cell transplant in people with relapsed or hard-to-treat CD7-positive leukemia. The goal is to help control the leukemia and improve chances for a successful transplant.
Hangzhou, ZhejiangAges 18 years+ - NCT06680388RecruitingEarly Phase 1
CD19 CAR-T for severe autoimmune diseases
This trial tests whether a special immune cell treatment (CD19 CAR-T) can help people with certain severe autoimmune diseases that have not improved with standard therapies. It is a very early study to see if the treatment is safe and effective for conditions like lupus, systemic sclerosis, vasculitis, myositis, or Sjögren's syndrome.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT06676982RecruitingPhase 1
CAR-T cell therapy for advanced liver cancer
This trial tests a new treatment called CNCT19, which uses your own immune cells to fight liver cancer. It's for people with advanced liver cancer that hasn't responded to standard treatments or can't be treated with surgery or local procedures.
Hangzhou, ZhejiangAges 18–80 - NCT06658951Recruiting
HER2-targeted CAR-T cell therapy for advanced solid tumors
This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack cancer cells that have a high amount of a protein called HER2. It is for people with advanced solid tumors (like certain breast, stomach, or lung cancers) that have not responded to standard treatments.
Zhengzhou, HenanAges 18–70 - NCT06652633RecruitingPhase 3
Long-term follow-up of Galapagos CAR T-cell therapy recipients
This study is for people who have already received a specific type of cell therapy (CAR T-cell therapy) made by Galapagos. It will follow them over the long term to see how they are doing.
Boston, MassachusettsAges 18 years+
Hear when a new CAR trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for car?
- Yes. Clin2 currently lists 733 recruiting car studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a car trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a car trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.